Search hospitals > Missouri > Bonne Terre
Parkland Health Center-Bonne Terre
Claim this profileBonne Terre, Missouri 63628
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
166 reported clinical trials
2 medical researchers
Summary
Parkland Health Center-Bonne Terre is a medical facility located in Bonne Terre, Missouri. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Recurrence and other specialties. Parkland Health Center-Bonne Terre is involved with conducting 166 clinical trials across 388 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Lung Cancer
Global LeaderStage IV
Stage I
Stage II
Top PIs
Bryan A. FallerCrossroads Cancer Center2 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
226 reported clinical trials
291 drugs studied
James L. WadeDecatur Memorial Hospital3 years of reported clinical research
Studies Recurrence
Studies Breast Cancer
11 reported clinical trials
20 drugs studied
Clinical Trials running at Parkland Health Center-Bonne Terre
Non-Small Cell Lung Cancer
Bladder Carcinoma
Bladder Cancer
Cancer
Lung Cancer
Breast Cancer
Renal Cell Carcinoma
Ovarian Tumors
Ovarian Carcinoma
Anal Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Osimertinib
for Non-Small Cell Lung Cancer
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Recruiting1 award Phase 242 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Parkland Health Center-Bonne Terre?
Parkland Health Center-Bonne Terre is a medical facility located in Bonne Terre, Missouri. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Recurrence and other specialties. Parkland Health Center-Bonne Terre is involved with conducting 166 clinical trials across 388 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.